Arca
Skip to content
Tools
Tools

Serotonin 3 (5-HT3) receptor

Complex group in Homo sapiens that 8 drugs act on.

  • Drugs that act on it: 8
  • Approved: 2
  • In phases 1 to 3: 6
  • Sponsors: 6
  • Genes: 5

Who is on it, and how far along

Every drug ChEMBL records acting on HTR3A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 8

Approved2

  • Tropisetron
  • Ramosetron

Phase 32

  • Mosapride
  • Renzapride

Phase 24

  • Clothiapine
  • Facinicline
  • Pumosetrag
  • Tedatioxetine

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Alizyme113%
    • Dynogen Pharmaceuticals113%
    • IlDong Pharmaceutical Co Ltd113%
    • Memory Pharmaceuticals113%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 7 of 8 act as: Serotonin 3 (5-HT3) receptor antagonist; the rest name their own mechanism.
    TropisetronApproved—Small moleculeAntagonist7
    RamosetronApprovedAstellas PharmaSmall moleculeAntagonist4
    MosapridePhase 3IlDong Pharmaceutical Co LtdSmall moleculeAntagonist4
    RenzapridePhase 3AlizymeSmall moleculeAntagonist0
    ClothiapinePhase 2—Small moleculeAntagonist0
    FaciniclinePhase 2Memory PharmaceuticalsSmall moleculeAntagonist0
    PumosetragPhase 2Dynogen PharmaceuticalsSmall moleculePartial agonistSerotonin 3 (5-HT3) receptor partial agonist0
    TedatioxetinePhase 2H. Lundbeck A/SSmall moleculeAntagonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 15 in all, from ClinicalTrials.gov.
    Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationTropisetronNot applicableRecruitingChina National Center for Cardiovascular DiseasesOct 16, 2026
    Clinical Study on the Treatment of Gastrointestinal Dysfunction After Knee Joint Surgery Under General Anesthesia With Floating NeedleMosaprideNot applicableEnrolling by invitationZhenyu ZhangMay 26, 2026
    Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel SyndromeRamosetronPhase 4Not yet recruitingMd. Aminul IslamMay 7, 2026
    Amisulpride for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic SurgeryTropisetron—Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineApr 28, 2026
    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing RegimenTropisetronPhase 3RecruitingThe Affiliated People's Hospital of Ningbo UniversityFeb 17, 2026
    Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional DyspepsiaMosapridePhase 4RecruitingXijing Hospital of Digestive DiseasesSep 19, 2025
    The Effect of Two Prokinetics in Patients With Functional DyspepsiaMosaprideNot applicableActive, not recruitingEunpyeong St. Mary's HospitalJul 31, 2025
    Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast CancerTropisetronPhase 3RecruitingJiuda ZhaoMay 1, 2025
    A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill PatientsMosapridePhase 3Not yet recruitingAin Shams UniversityFeb 14, 2025
    Minimum Effective Dose of Incisional Local Infiltration Betamethasone for the Prevention of Pain After Spinal SurgeryTropisetronNot applicableRecruitingBeijing Tiantan HospitalJan 21, 2025
    Study on the Effects of Multimodal Analgesia Regimens on Postoperative Analgesia and Gastrointestinal Function Recovery After Laparoscopic Abdominal SurgeryTropisetronNot applicableNot yet recruitingXiaguang DuanJan 13, 2025
    Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast CancerTropisetronPhase 3RecruitingJiuda ZhaoJan 10, 2024
    Analgesic Efficacy of Maxigesic in Breast Cancer SurgeryRamosetronNot applicableRecruitingYonsei UniversityDec 18, 2023
    The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal IncontinenceRamosetronPhase 2 / Phase 3Active, not recruitingSeoul National University HospitalDec 12, 2023
    5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)RamosetronNot applicableRecruitingSeoul National University HospitalOct 13, 2022

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2094132, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.